Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
AssigneesThe General Hospital Corporation, President and Fellows of Harvard College
InventorsJ. Keith Joung, Peter Cabeceiras
Life of this patent
Estimating the term…
Abstract
Human-derived virus-like particles (heVLPs), comprising a membrane comprising a phospholipid bilayer with one or more HERV-derived envelope proteins on the external side; one or more HERV-derived GAG proteins in the heVLP core, and a cargo molecule, e.g., a biomolecule and/or chemical cargo molecule, disposed in the core of the heVLP on the inside of the membrane, wherein the heVLP does not comprise a gag protein, except for gag proteins that are encoded in the human genome or gag proteins that are encoded by a consensus sequence that is derived from gag proteins found in the human genome, and methods of use thereof for delivery of the cargo molecule to cells.
Claims29
An engineered particle, comprising:
- (a) a phospholipid bilayer membrane comprising a human endogenous retrovirus (HERV) glycoprotein;
- (b) a HERV GAG protein encapsulated within the phospholipid bilayer membrane;
- and
- (c) a therapeutic cargo encapsulated within the phospholipid bilayer membrane, wherein the therapeutic cargo comprises a protein, wherein the therapeutic cargo is fused with a plasma membrane recruitment domain, and wherein the plasma membrane recruitment domain is not a viral gag protein or a CD63 protein.
An engineered particle, comprising:
- (a) a phospholipid bilayer membrane comprising a human endogenous retrovirus (HERV) glycoprotein;
- and
- (b) a therapeutic cargo encapsulated within the phospholipid bilayer membrane, wherein the therapeutic cargo is fused with a plasma membrane recruitment domain, wherein the plasma membrane recruitment domain is not a viral gag protein or a CD63 protein.
Dependencies are inferred from the claim text.